Chest Email Content Delivery
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Guest Access | Sign In via User Name/Password
This Article
Right arrow Full Text Free
Right arrow Full Text (PDF) Free
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Article Archive
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via ISI Web of Science (10)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Fulgoni, P.
Right arrow Articles by Cerveri, I.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Fulgoni, P.
Right arrow Articles by Cerveri, I.
(Chest. 1999;116:1163-1167.)
© 1999 American College of Chest Physicians

Lung Function in Survivors of Childhood Acute Lymphoblastic Leukemia*

Paola Fulgoni, MD; Maria Cristina Zoia, MD; Angelo Corsico, MD; Massimiliano Beccaria, MD; Giovanna Georgiani, MD; Grazia Bossi, MD and Isa Cerveri, MD

* From the Institute of Respiratory Diseases (Drs. Fulgoni, Zoia, Corsico, Beccaria, and Cerveri), and Department of Pediatrics (Drs. Georgiani and Bossi), IRCCS Policlinico "S. Matteo," University of Pavia, Italy.

Correspondence to: Isa Cerveri, MD, Istituto Forlanini, IRCCS, Policlinico "S. Matteo," Universita’ di Pavia, via Taramelli 5, 27100 Pavia, Italy; e-mail: isa{at}mbox.systemy.it

Study objectives: To evaluate lung function in patients cured from childhood acute lymphoblastic leukemia (ALL) with chemotherapy alone or plus bone marrow transplantation (BMT). Pulmonary toxicity is a well-recognized side effect of many ALL treatments.

Design: Cross-sectional study conducted at least 3 years after cessation of therapy.

Setting: Outpatient pneumology department of the University Hospital.

Patients: Forty-four subjects (age range at observation, 6 to 23 years): 21 treated only with intensive Berlin-Frankfurt-Munster (BFM)-type chemotherapy for newly diagnosed ALL (group A), and 23 treated with chemotherapy plus BMT (group B).

Measurements: A detailed history of smoking habit, respiratory symptoms, and diseases was recorded directly from the patients with the aid of their parents. A complete physical examination and lung function testing (lung volumes and diffusion capacity for carbon monoxide [DLCO]) were performed in all subjects.

Results: No patient reported acute or chronic respiratory symptoms or diseases. In group A patients, lung function was in the normal range, except for three subjects in whom there was an isolated impairment of DLCO. In group B patients, lung function was markedly impaired, with more than half the patients having an abnormal DLCO. A statistically significant difference was found between the two groups for FVC (p = 0.022) and DLCO (p = 0.004).

Conclusions: Intensive, BFM-type frontline chemotherapy is not associated with late pulmonary dysfunction; however, retreatment including BMT can frequently injure the lung. Thus, in patients who undergo BMT and whose life expectancy is long, careful monitoring of lung function and counseling about avoiding additional lung risk factors is recommended.

Key Words: acute lymphoblastic leukemia • long-term lung function






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1999 by the American College of Chest Physicians.